Literature DB >> 170206

Neutralizing antibody responses to varicella-zoster virus.

N J Schmidt, E H Lennette.   

Abstract

Neutralization of varicella-zoster (V-Z) virus by human sera and immune rhesus monkey sera was enhanced by fresh guinea pig complement. There was no marked difference in the degree to which complement enhanced neutralization by sera from current V-Z virus infections and sera from long-past varicella infections. Immunoglobulin G neutralizing antibody in sera from varicella cases was enhanced by complement to a slightly higher degree than was immunoglobulin M (IgM) antibody, and immunoglobulin G neutralizing antibody in immune monkey sera was enhanced to a much greater degree than was IgM antibody. There was a rapid decline in the complement requirement of IgM neutralizing antibodies over the course of immunization of the rhesus monkeys. V-Z neutralizing antibody titers in the presence of complement were higher than complement-fixing titers of the same sera in all groups of individuals studied. IgM neutralizing antibody for V-Z virus was demonstrable in all cases of varicella but in only 1 of 22 zoster cases, and V-Z IgM neutralizing antibody was not detectable in primary herpes simplex virus infections in which heterotypic antibody titer rises occurred to V-Z virus. Complement-fixing antibody for V-Z virus was absent in 19S serum fractions which contained IgM neutralizing antibody for the virus.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 170206      PMCID: PMC415330          DOI: 10.1128/iai.12.3.606-613.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  A COMPLEMENT-FIXING ANTIGEN FOR VARICELLA-ZOSTER DERIVED FROM INFECTED CULTURES OF HUMAN FETAL DIPLOID CELLS.

Authors:  N J SCHMIDT; E H LENNETTE; C W SHON; T T SHINOMOTO
Journal:  Proc Soc Exp Biol Med       Date:  1964-05

2.  CHARACTERIZATION OF ANTIBODIES PRODUCED BY GUINEA PIGS INOCULATED WITH INACTIVATED FOOT-AND-MOUTH DISEASE ANTIGEN.

Authors:  J H GRAVES; K M COWAN; R TRAUTMAN
Journal:  J Immunol       Date:  1964-04       Impact factor: 5.422

3.  GROWTH OF VARICELLA-ZOSTER VIRUS IN HUMAN THYROID TISSUE CULTURES.

Authors:  A E CAUNT
Journal:  Lancet       Date:  1963-11-09       Impact factor: 79.321

4.  THE NATURE OF ANTIBODIES FOLLOWING EXPERIMENTAL ARBOVIRUS INFECTION IN GUINEA PIGS.

Authors:  J A BELLANTI; S B RUSS; G E HOLMES; E L BUESCHER
Journal:  J Immunol       Date:  1965-01       Impact factor: 5.422

5.  POSSIBLE ANTIGENIC RELATIONSHIP BETWEEN VARICELLA ZOSTER VIRUS AND HERPES SIMPLEX VIRUS.

Authors:  J G KAPSENBERG
Journal:  Arch Gesamte Virusforsch       Date:  1964-09-09

6.  A possible role of gamma-A-immunoglobulin in herpes simplex virus infection in man.

Authors:  T Tokumaru
Journal:  J Immunol       Date:  1966-08       Impact factor: 5.422

7.  Immunoglobulins produced in response to Japanese encephalitis virus infections of man.

Authors:  K Ishii; Y Matsunaga; R Kono
Journal:  J Immunol       Date:  1968-10       Impact factor: 5.422

8.  Immunofluorescent staining in the laboratory diagnosis of varicella-zoster virus infections.

Authors:  N J Schmidt; E H Lennette; J D Woodie; H H Ho
Journal:  J Lab Clin Med       Date:  1965-09

9.  Antigenic relationship of varicella-zoster and herpes simplex.

Authors:  C A Ross; J H Subak Sharpe; P Ferry
Journal:  Lancet       Date:  1965-10-09       Impact factor: 79.321

10.  The etiologic agents of varicella and herpes zoster; isolation, propagation, and cultural characteristics in vitro.

Authors:  T H WELLER; H M WITTON; E J BELL
Journal:  J Exp Med       Date:  1958-12-01       Impact factor: 14.307

View more
  29 in total

1.  Antibody assays for varicella-zoster virus: comparison of enzyme immunoassay with neutralization, immune adherence hemagglutination, and complement fixation.

Authors:  B Forghani; N J Schmidt; J Dennis
Journal:  J Clin Microbiol       Date:  1978-11       Impact factor: 5.948

2.  Analysis of antibody assay methods and classes of viral antibodies in serodiagnosis of cytomegalovirus infection.

Authors:  N E Cremer; M Hoffman; E H Lennette
Journal:  J Clin Microbiol       Date:  1978-08       Impact factor: 5.948

3.  Varicella-zoster plaque assay and plaque reduction neutralization test by the immunoperoxidase technique.

Authors:  G Gerna; R W Chambers
Journal:  J Clin Microbiol       Date:  1976-11       Impact factor: 5.948

4.  Improved yields of cell-free varicella-zoster virus.

Authors:  N J Schmidt; E H Lennette
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

5.  Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein.

Authors:  C M Edson; B A Hosler; R A Respess; D J Waters; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

6.  Development of an immunofluorescence test for the serodiagnosis of herpes zoster ophthalmicus.

Authors:  P Walpita; S Darougar; R J Marsh; M Cooper
Journal:  Br J Ophthalmol       Date:  1986-06       Impact factor: 4.638

7.  Sensitivity of different assay systems for immunoglobulin M responses to varicella-zoster virus in reactivated infections (zoster).

Authors:  N J Schmidt; A M Arvin
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

8.  Role of rheumatoid factor in complement fixation and indirect hemagglutination tests for immunoglobulin M antibody to cytomegalovirus.

Authors:  N E Cremer; M Hoffman; E H Lennette
Journal:  J Clin Microbiol       Date:  1978-08       Impact factor: 5.948

Review 9.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.